Different Volumes of Articaine for Inferior Alveolar Nerve Block in Irreversible Pulpitis (IANB)
Drug Effect, Pulpitis - Irreversible
About this trial
This is an interventional treatment trial for Drug Effect
Eligibility Criteria
Inclusion Criteria: Healthy patients, including age group 18-55 years old Mandibular first molar tooth with symptomatic irreversible pulpitis Normal periapical radiographic appearance Moderate pain on Heft-Parker VAS ( > 54 mm and < 114 mm ) Lingering pain or prolonged response to the cold testing (more than 10 seconds) Positive response to electric pulp testing Exclusion Criteria: Patients who have taken analgesic or anti-inflammatory drugs within 6 hours before treatment visit History of allergy to 4% articaine or epinephrine Patients with systemic diseases Pregnant or lactating patients Teeth with severe periodontal disease Teeth with periapical radiolucency Any type of medication that could potentially interact with the anesthetic solution (antihypertensives)
Sites / Locations
- Armed Forces Institue Of DentistryRecruiting
- Armed Forces Institute of DentistryRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
1.8 ml group
3.6 ml group
Participants in this group will be given 1 cartridge of articaine solution pre-operatively to endodontic treatment
Participants in this group will be given 2 cartridges of articaine solution pre-operatively to endodontic treatment